FDA clears DermaSensor’s AI detection device for skin cancer

January 18, 2024
Medical Communications FDA, Oncology, skin cancer

DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …

Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment

January 18, 2024
Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial

Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …

FDA clears Aruna Bio’s IND for AB126 to enter clinical trials

January 17, 2024
Research and Development Aruna Bio, FDA, IND, Neurology, clinical trials

Aruna Bio has announced that the US Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application …

Qlucore and Sahlgrenska Hospital sign agreement for ALL diagnosis software

January 17, 2024
Business Services Oncology, Qlucore, Sahlgrenska Hospital, acute lymphoblastic leukaemia, leukaemia

Qlucore has announced that it has entered into an agreement with Sahlgrenska Hospital, in Gothenberg, Sweden. This agreement means the …

Upperton Pharma Solutions announces £5m investment into sterile drug manufacturing

January 16, 2024
Manufacturing and Production Pharmacy, Upperton Pharma Solutions, investment, sterile drug manufacturing

UK-based contract development and manufacturing organisation (CDMO), Upperton Pharma Solutions has announced a £5m investment to expand into a small-scale …

DelSiTech announces closing of €10m financing round for silica-based drug delivery platform

January 16, 2024
Manufacturing and Production DelSiTech, Pharmacy, drug delivery, investment, manufacturing

DelSiTech has announced the successful completion of a €10m financing round, marking the largest single financing round in the company’s …

FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment

January 15, 2024
Medical Communications FDA, Oncology, cervical cancer, keytruda

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …

Boan Biotech completes enrolment for phase 3 study of Denosumab

January 15, 2024
Research and Development Boan Biotech, Pharmacy, biosimilar, clinical trial, denosumab

Boan Biotech has announced that it has completed subject enrolment for its international multicentre comparative phase 3 clinical trial of …

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

January 12, 2024
Medical Communications COVID-19, Infections and infestations, NICE

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …

Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy

January 12, 2024
Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera

Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …

Venatorx and Menarini enter commercial agreement for cefepime-taniborbactam

January 11, 2024
Sales and Marketing Infections and infestations, Menarini Group, Venatorx Pharmaceuticals, cefepime-taniborbactam, collaboration

Venatorx Pharmaceuticals and Menarini Group have announced that they have entered into a commercial agreement valid in 96 countries in …

Isomorphic Labs to collaborate with Eli Lilly

January 11, 2024
Research and Development AI, Eli Lilly, Isomorphic Labs, Pharmacy, drug discovery

Isomorphic Labs has announced that it has entered into a strategic research collaboration with Eli Lilly and Company, marking the …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

January 10, 2024
Research and Development Diabetes, IcoSema, Novo Nordisk, clinical trial, diabetes

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly IcoSema, a fixed-ration combination treatment …

Merck to acquire Harpoon Therapeutics for approximately $680m

January 10, 2024
Business Services Harpoon Therapeutics, MSD, Merck, Oncology, acquisition

Merck (known as MSD outside of the US and Canada) and Harpoon Therapeutics have announced that they have entered a …

Fate Therapeutics initiates phase 1 trial for solid tumour treatment

January 9, 2024
Research and Development Fate Therapeutics, Oncology, solid tumours

Fate Therapeutics has announced that it has begun enrollment for the phase 1 clinical trial of FT825/ONO-8250, a multiplexed-engineered, chimeric …

GSK to acquire Aiolos Bio for $1bn

January 9, 2024
Business Services Aiolos Bio, GSK, Pharmacy, acquisition

GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an …

Consilient Health to launch Cytisine smoking cessation treatment in UK

January 8, 2024
Sales and Marketing Cytisine, Smoking Cessation, consilient health, smoking cessation

Consilient Health has announced that it plans to launch Cytisine 1.5mg tablets in the UK on 22 January 2024. The …

Calypso Biotech to be acquired by Novartis for $250m

January 8, 2024
Business Services Calypso Biotech, Immunology, Novartis, acquisition

Calypso Biotech has announced that it has entered into an agreement to be acquired by Novartis. The company’s shareholders will …

national-cancer-institute-l8twzt4ccvq-unsplash_1

Eli Lilly launches digital healthcare process

January 5, 2024
Medical Communications Diabetes, Eli Lilly, Obesity, diabetes, obesity

Eli Lilly has announced its new digital healthcare experience, LillyDirect, which will benefit patients in the US with obesity, migraine …

Rhythm Pharmaceuticals and LG Chem Life Sciences enter license agreement

January 5, 2024
Medical Communications LG Chem Life Sciences, License Agreement, Pharmacy, Rhythm Pharmaceuticals, clinical trial

Rhythm Pharmaceuticals and LG Chem Life Sciences have announced that they have entered into a global licensing agreement for LB54640, …

Latest content